Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

AmVac AG - Product Pipeline Review - 2015

Published: Feb-2015 | Format: PDF | Global Markets Direct | Number of pages: 27 | Code: MRS - 7037

 

Global Markets Direct’s, ‘AmVac AG Product Pipeline Review 2015’, provides an overview of the AmVac AG’s pharmaceutical research and development focus.

 

This report provides comprehensive information on the current therapeutic developmental pipeline of AmVac AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

 

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

The report provides brief overview of AmVac AG including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of AmVac AG’s human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement 
Latest news and deals relating to the AmVac AG’s pipeline products

 

Reasons to buy

 

Evaluate AmVac AG’s strategic position with total access to detailed information on its product pipeline
Assess the growth potential of AmVac AG in its therapy areas of focus
Identify new drug targets and therapeutic classes in the AmVac AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of AmVac AG and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of AmVac AG
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of AmVac AG and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues

Table of Contents
 

 

Table of Contents 2
List of Tables 4
List of Figures 4
AmVac AG Snapshot 5
AmVac AG Overview 5
Key Information 5
Key Facts 5
AmVac AG - Research and Development Overview 6
Key Therapeutic Areas 6
AmVac AG - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
AmVac AG - Pipeline Products Glance 10
AmVac AG - Late Stage Pipeline Products 10
Phase III Products/Combination Treatment Modalities 10
AmVac AG - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
AmVac AG - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
AmVac AG - Drug Profiles 13
AMV-100 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
AMV-110 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
AMV-401 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
AMV-411 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
AMV-601 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
AMV-602 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
AMV-603 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
AMV-611 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
AmVac AG - Pipeline Analysis 21
AmVac AG - Pipeline Products by Route of Administration 21
AmVac AG - Pipeline Products by Molecule Type 22
AmVac AG - Recent Pipeline Updates 23
AmVac AG - Dormant Projects 24
AmVac AG - Locations And Subsidiaries 25
Head Office 25

 

Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 26
Disclaimer 27


 

List of Tables
 

 

AmVac AG, Key Information 5
AmVac AG, Key Facts 5
AmVac AG - Pipeline by Indication, 2015 7
AmVac AG - Pipeline by Stage of Development, 2015 8
AmVac AG - Monotherapy Products in Pipeline, 2015 9
AmVac AG - Phase III, 2015 10
AmVac AG - Phase II, 2015 11
AmVac AG - Preclinical, 2015 12
AmVac AG - Pipeline by Route of Administration, 2015 21
AmVac AG - Pipeline by Molecule Type, 2015 22
AmVac AG - Recent Pipeline Updates, 2015 23
AmVac AG - Dormant Developmental Projects,2015 24

 

List of Figures
 

AmVac AG - Pipeline by Top 10 Indication, 2015 7
AmVac AG - Pipeline by Stage of Development, 2015 8
AmVac AG - Monotherapy Products in Pipeline, 2015 9
AmVac AG - Pipeline by Top 10 Route of Administration, 2015 21
\AmVac AG - Pipeline by Top 10 Molecule Type, 2015 22

 

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)1500 View Pricing